Skip to main content
    I

    Immuneering Corp (IMRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.46
    -0.06 (-1.70%)

    Market Cap: $240.27M

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Immuneering Corp (IMRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Immuneering (IMRX) has a market cap of $240.27M and an enterprise value of $198.95M. Its share count is up 79.79% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 17.20% below the market cap, as cash exceeds debt.

    Market Cap$240.27M
    Enterprise Value$198.95M
    Latest price (Nov 17, 2026)$3.46

    Key Dates

    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.06% in the quarter ended Jun 30, 2026 and grew 47.71% a year over 2 years.

    Shares Outstanding64.70M
    Shares Change (YoY)+79.79%
    Shares Change (QoQ)+0.06%
    Share Count Growth (2Y CAGR)+47.71%

    Valuation Ratios

    P/B Ratio1.2x
    P/TBV Ratio1.2x

    Price Statistics

    The stock is down 45.51% over 52 weeks and trades 12.18% below its 50-day average.

    Beta (1Y)1.37
    52-Week Change-45.51%
    1-Month Change-5.46%
    3-Month Change-35.08%
    6-Month Change-29.24%
    5-Year Change-86.18%
    Total Return (1Y)-45.51%
    Total Return (3Y CAGR)-14.83%
    Total Return (5Y CAGR)-33.26%
    Return vs SPY (1Y)-63.17%
    Max Drawdown (1Y)-59.54%
    Max Drawdown (3Y)-87.80%
    Sharpe Ratio (1Y)-0.82
    Correlation with SPY (1Y)0.21
    50-Day Average$3.94
    200-Day Average$4.73
    52-Week Range$3.35 to $8.48
    RSI (14 Days)41.3
    Average Volume (20 Days)794.96K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 19.47x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio19.47x
    Quick Ratio19.47x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -30.03% over the last 12 months, against a 5-year average of -59.93%.

    Return on Equity (ROE)-30.03%
    Return on Assets (ROA)-28.35%
    ROE (5Y Average)-59.93%
    ROA (5Y Average)-50.69%
    ROIC (5Y Average)-21.47%

    Scores

    IMRX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$612.73K
    Operating Income-$63.47M
    Pretax Income-$58.10M
    Net Income-$57.28M
    Reported EPS (TTM)-$1.03

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 94.40% of the $202.06M in total assets.

    Cash and Equivalents$41.32M
    Total Debt$0
    Net Cash$41.32M
    Net Cash Per Share$0.64
    Working Capital$149.87M
    Shareholder Equity$190.74M
    Book Value Per Share$2.95
    Tangible Book Value$183.74M
    Tangible Book Per Share$2.84
    Total Assets$202.06M
    Total Liabilities$11.32M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $238.46K of capital spending, operating cash flow left -$56.99M of free cash flow.

    Operating Cash Flow-$56.75M
    Capital Expenditures$238.46K
    Free Cash Flow-$56.99M
    FCF Per Share-$0.88
    Depreciation and Amortization$1.45M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+26.66%
    Tangible Book Per Share Growth (2Y CAGR)+29.78%

    Revenue and profit by year

    Dividends and Yields

    IMRX does not pay a dividend. Its free cash flow yield is -25.46%.

    FCF Yield-25.46%
    Buyback Yield-94.99%
    Shareholder Yield-94.99%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IMRX

    What is IMRX's market cap?

    Immuneering has a market cap of $240.27M. Its enterprise value, which adds debt and subtracts cash, is $198.95M.

    How many shares of IMRX are outstanding?

    Immuneering has 64.70M shares outstanding. The count is up 79.79% from a year earlier.

    Does IMRX pay a dividend?

    No. Immuneering does not pay a dividend.

    How much debt does IMRX have?

    Immuneering has $0 of total debt and $41.32M of cash and equivalents, a net cash position of $41.32M.